Search

Author/Creator Koller, Paul

1. Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia. Issue 3 (11th October 2021)

Authors:
Aldoss, Ibrahim; Otoukesh, Salman; Zhang, Jianying; Mokhtari, Sally; Ngo, Dat; Mojtahedzadeh, Mona; Al Malki, Monzr M.; Salhotra, Amandeep; Ali, Haris; Aribi, Ahmed; Sandhu, Karamjeet S.; Arslan, Shukaib; Koller, Paul; Ball, Brian; Stewart, Forrest; Curtin, Peter; Artz, Andrew; Nakamura, Ryotaro;...
Journal:
Cancer
Issue:
Volume 128:Issue 3(2022)
Page Start:
529
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Venetoclax and hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukaemia. (21st December 2021)

Authors:
Salhotra, Amandeep; Tsai, Ni‐Chun; Zhang, Jianying; Ngo, Dat; Aribi, Ahmed; Sandhu, Karamjeet; Ball, Brian; Al‐Malki, Monzr; Ali, Haris; Koller, Paul; Artz, Andrew; Forman, Stephen; Nakamura, Ryotaro; Stein, Anthony; Marcucci, Guido; Aldoss, Ibrahim; Pullarkat, Vinod
Journal:
British journal of haematology
Issue:
Volume 196:Number 6(2022)
Page Start:
e71
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA‐Ven) or liposomal daunorubicin‐cytarabine (CPX‐351). Issue 6 (8th April 2021)

Authors:
Salhotra, Amandeep; Aribi, Ahmed; Ngo, Dat; Zhang, Jianying; Sandhu, Karamjeet; Al‐Malki, Monzr; Ali, Haris; Koller, Paul; Arslan, Shukaib; Budde, Elizabeth; Khaled, Samer; Dadwal, Sanjeet; Snyder, David S.; Artz, Andrew; Forman, Stephen; Nakamura, Ryotaro; Stein, Anthony; Marcucci, Guido; Aldoss...
Journal:
American journal of hematology
Issue:
Volume 96:Issue 6(2021)
Page Start:
E196
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML). Issue 13 (10th November 2022)

Authors:
Ball, Brian J.; Arslan, Shukaib; Koller, Paul; Ngo, Dat; Afkhami, Michelle; Salhotra, Amandeep; Al-Malki, Monzr; Aribi, Ahmed; Ali, Haris; Sandhu, Karamjeet; Otoukesh, Salman; Amanam, Idoroenyi; Pourhassan, Hoda; Artz, Andrew; Curtin, Peter; Stein, Anthony; Nakamura, Ryotaro; Marcucci, Guido; Smi...
Journal:
Leukemia & lymphoma
Issue:
Volume 63:Issue 13(2022)
Page Start:
3232
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Venetoclax and hypomethylating agents in FLT3‐mutated acute myeloid leukemia. Issue 10 (28th July 2020)

Authors:
Aldoss, Ibrahim; Zhang, Jianying; Mei, Matthew; Al Malki, Monzr M; Arslan, Shukaib; Ngo, Dat; Aribi, Ahmed; Ali, Haris; Sandhu, Karamjeet; Salhotra, Amandeep; Koller, Paul; Khaled, Samer; Artz, Andrew; Snyder, David; Nakamura, Ryotaro; Forman, Stephen J; Stein, Anthony S.; Marcucci, Guido; Pullar...
Journal:
American journal of hematology
Issue:
Volume 95:Issue 10(2020:Oct.)
Page Start:
1193
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗